Building upon the understanding of ASCL1 in cancer biology, the study by Zhou et al. [39] explores its critical role in NE differentiation and proliferation within small cell lung cancer (SCLC) tissues from patients with non-small cell lung adenocarcinoma (LUAD) resistant to EGFR tyrosine kinase inhibitors (TKIs). Here, EGFR is linked to non-small cell lung adenocarcinoma.